| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.95 | 0.001 | 0.95 | Potassium channel large-conductance Ca-activated activator | 0.786 0.001 CID_154699763 | ||
| 0.881 | 0.005 | 0.881 | Toll-Like receptor 7 agonist | 0.732 0.007 CID_154699763 | ||
| 0.879 | 0.005 | 0.879 | Toll-Like receptor agonist | 0.728 0.007 CID_154699763 | ||
| 0.796 | 0.004 | 0.796 | Anticonvulsant | 0.353 0.029 CID_154699763 | ||
| 0.787 | 0.002 | 0.787 | Potassium channel (Ca-activated) activator | 0.301 0.005 CID_154699763 | ||
| 0.569 | 0.062 | 0.569 | Antiinflammatory | 0.353 0.17 CID_154699763 | ||
| 0.411 | 0.004 | 0.411 | Potassium channel activator | |||
| 0.387 | 0.071 | 0.387 | Antiobesity | |||
| 0.375 | 0.095 | 0.375 | 5 Hydroxytryptamine release inhibitor | |||
| 0.273 | 0.004 | 0.273 | 5 Hydroxytryptamine 2C agonist | 0.077 0.012 CID_154699763 | ||
| 0.304 | 0.06 | 0.304 | Aryl hydrocarbon receptor agonist | |||
| 0.359 | 0.141 | 0.359 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.21 | 0.004 | 0.21 | 5 Hydroxytryptamine 2A agonist | |||
| 0.206 | 0.014 | 0.206 | 5 Hydroxytryptamine agonist | |||
| 0.29 | 0.102 | 0.29 | Calcium channel activator | |||
| 0.19 | 0.006 | 0.19 | Potassium channel (Voltage-sensitive) activator | |||
| 0.178 | 0.015 | 0.336 | AMP-activated protein kinase stimulant | 0.336 0.004 CID_154699763 | CID_154699763 | |
| 0.179 | 0.038 | 0.179 | Sodium channel (voltage-gated) blocker | |||
| 0.145 | 0.005 | 0.145 | 5 Hydroxytryptamine 2 agonist | |||
| 0.233 | 0.098 | 0.233 | 5 Hydroxytryptamine release stimulant | |||
| 0.16 | 0.038 | 0.16 | Pregnane X receptor agonist | |||
| 0.177 | 0.058 | 0.177 | Death-associated protein kinase 2 inhibitor | |||
| 0.109 | 0.004 | 0.109 | 5 Hydroxytryptamine 2B agonist | |||
| 0.159 | 0.055 | 0.159 | Cytokine production inhibitor | |||
| 0.138 | 0.035 | 0.138 | Nav1.5 sodium channel blocker | |||
| 0.168 | 0.074 | 0.168 | ATPase inhibitor | |||
| 0.103 | 0.012 | 0.103 | Aryl hydrocarbon receptor antagonist | |||
| 0.148 | 0.059 | 0.148 | Sodium channel blocker | |||
| 0.17 | 0.085 | 0.17 | MAP kinase kinase 5 inhibitor | |||
| 0.117 | 0.035 | 0.117 | Androgen antagonist | |||
| 0.266 | 0.188 | 0.266 | Calcium channel L-type activator | |||
| 0.082 | 0.005 | 0.082 | Potassium channel KCNQ activator | |||
| 0.082 | 0.005 | 0.082 | Delayed rectifier potassium channel activator | |||
| 0.099 | 0.023 | 0.099 | Nav1.7 sodium channel blocker | |||
| 0.086 | 0.014 | 0.086 | MDM2 inhibitor | |||
| 0.076 | 0.016 | 0.08 | Lipocortins synthesis agonist | 0.08 0.014 CID_154699763 | CID_154699763 | |
| 0.09 | 0.033 | 0.09 | Prostaglandin-E synthase inhibitor | |||
| 0.15 | 0.095 | 0.15 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.137 | 0.086 | 0.137 | Ca2+-transporting ATPase inhibitor | |||
| 0.083 | 0.035 | 0.083 | Vanilloid 1 antagonist | |||
| 0.164 | 0.118 | 0.164 | Neurotrophic factor enhancer | |||
| 0.075 | 0.032 | 0.075 | NMDA receptor glycine site agonist | |||
| 0.127 | 0.085 | 0.127 | Nav1.6 sodium channel blocker | |||
| 0.075 | 0.033 | 0.075 | Exportin-1 inhibitor | |||
| 0.07 | 0.03 | 0.07 | Androgen agonist | |||
| 0.063 | 0.024 | 0.063 | Pregnane X receptor antagonist | |||
| 0.092 | 0.057 | 0.092 | Glutamate release inhibitor | |||
| 0.101 | 0.068 | 0.101 | Beta glucuronidase inhibitor | |||
| 0.078 | 0.045 | 0.078 | Nav1.8 sodium channel blocker | |||
| 0.057 | 0.037 | 0.057 | 5 Hydroxytryptamine 7 agonist | |||
| 0.04 | 0.022 | 0.04 | Progesterone antagonist | |||
| 0.139 | 0.122 | 0.139 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.17 | 0.153 | 0.17 | Nitric-oxide synthase stimulant | |||
| 0.061 | 0.052 | 0.061 | Calcium channel P-type blocker | |||
| 0.08 | 0.073 | 0.08 | Interleukin 5 antagonist | |||
| 0.092 | 0.085 | 0.092 | Polo-like kinase-4 inhibitor | |||
| 0.036 | 0.032 | 0.036 | Vanilloid 3 antagonist | |||
| 0.234 | 0.231 | 0.245 | Cyclophilin D inhibitor | 0.245 0.219 CID_154699763 | CID_154699763 | |
| 0.04 | 0.038 | 0.04 | Alpha 1L adrenoreceptor agonist | |||
| 0.034 | 0.033 | 0.034 | Glutamate (mGluR group II) antagonist | |||
| 0.011 | 0.01 | 0.011 | Glucocorticoid agonist | |||
| 0.018 | 0.02 | 0.021 | Corticosteroid-like | 0.021 0.015 CID_154699763 | CID_154699763 | |
| 0.236 | 0.271 | 0.31 | Caspase 9 stimulant | 0.31 0.183 CID_154699763 | CID_154699763 | |
| 0.104 | 0.15 | 0.14 | NOS3 expression enhancer | 0.14 0.083 CID_154699763 | CID_154699763 | |
| 0.139 | 0.228 | 0.195 | RNA-directed DNA polymerase inhibitor | 0.195 0.108 CID_154699763 | CID_154699763 | |
| 0.031 | 0.127 | 0.059 | Heparanase inhibitor | 0.059 0.025 CID_154699763 | CID_154699763 | |
| 0.138 | 0.243 | 0.38 | Cholesterol antagonist | 0.38 0.054 CID_154699763 | CID_154699763 | |
| 0.011 | 0.132 | 0.049 | Sodium/glucose cotransporter inhibitor | 0.049 0.005 CID_154699763 | CID_154699763 | |
| 0.049 | 0.194 | 0.134 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.134 0.032 CID_154699763 | CID_154699763 | |
| 0.112 | 0.257 | 0.152 | Heat shock protein 70 antagonist | 0.152 0.041 CID_154699763 | CID_154699763 | |
| 0.107 | 0.256 | 0.254 | Cyclic AMP phosphodiesterase inhibitor | 0.254 0.062 CID_154699763 | CID_154699763 | |
| 0.026 | 0.182 | 0.05 | Glucose-6-phosphate translocase inhibitor | 0.05 0.039 CID_154699763 | CID_154699763 | |
| 0.007 | 0.167 | 0.056 | Sodium/glucose cotransporter 2 inhibitor | 0.056 0.005 CID_154699763 | CID_154699763 | |
| 0.047 | 0.225 | 0.144 | NADH dehydrogenase inhibitor | 0.144 0.019 CID_154699763 | CID_154699763 | |
| 0.074 | 0.26 | 0.305 | Platelet adhesion inhibitor | 0.305 0.033 CID_154699763 | CID_154699763 | |
| 0.095 | 0.316 | 0.357 | Transcription factor NF kappa B inhibitor | 0.357 0.075 CID_154699763 | CID_154699763 | |
| 0.12 | 0.368 | 0.211 | Caspase 3 stimulant | 0.211 0.153 CID_154699763 | CID_154699763 | |
| 0.005 | 0.304 | 0.018 | Inosine monophosphate dehydrogenase 1 inhibitor | 0.018 0.015 CID_154699763 | CID_154699763 | |
| 0.022 | 0.326 | 0.069 | Purinergic P2X1 antagonist | 0.069 0.033 CID_154699763 | CID_154699763 | |
| 0.074 | 0.406 | 0.204 | Hypoxia-inducible factor 1 alpha inhibitor | 0.204 0.147 CID_154699763 | CID_154699763 | |
| 0.026 | 0.366 | 0.11 | UDP-glucose 4-epimerase inhibitor | 0.11 0.051 CID_154699763 | CID_154699763 | |
| 0.046 | 0.393 | 0.139 | Nitric oxide antagonist | 0.139 0.107 CID_154699763 | CID_154699763 | |
| 0.087 | 0.439 | 0.12 | CC chemokine 6 receptor antagonist | 0.12 0.115 CID_154699763 | CID_154699763 | |
| 0.043 | 0.449 | 0.149 | Hexokinase inhibitor | 0.149 0.08 CID_154699763 | CID_154699763 | |
| 0.066 | 0.474 | 0.155 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.155 0.138 CID_154699763 | CID_154699763 | |
| 0.024 | 0.442 | 0.063 | Adenine nucleotide translocase inhibitor | 0.063 0.024 CID_154699763 | CID_154699763 | |
| 0.011 | 0.439 | 0.031 | Purinergic P2Y2 antagonist | 0.031 0.028 CID_154699763 | CID_154699763 | |
| 0.005 | 0.435 | 0.02 | Adenosine A3 receptor agonist | 0.02 0.009 CID_154699763 | CID_154699763 | |
| 0.021 | 0.473 | 0.113 | Uric acid excretion stimulant | 0.113 0.043 CID_154699763 | CID_154699763 | |
| 0.047 | 0.517 | 0.324 | Immunosuppressant | 0.324 0.101 CID_154699763 | CID_154699763 | |
| 0.016 | 0.511 | 0.107 | Aminoacyl-tRNA synthetase inhibitor | 0.107 0.038 CID_154699763 | CID_154699763 | |
| 0.01 | 0.523 | 0.053 | Protein 50S ribosomal subunit inhibitor | 0.053 0.037 CID_154699763 | CID_154699763 | |
| 0.027 | 0.567 | 0.155 | Insulin secretagoues | 0.155 0.069 CID_154699763 | CID_154699763 | |
| 0.001 | 0.56 | 0.014 | Purinergic P2 agonist | 0.014 0.012 CID_154699763 | CID_154699763 | |
| 0.001 | 0.56 | 0.014 | Purinergic receptor agonist | 0.014 0.012 CID_154699763 | CID_154699763 | |
| 0.058 | 0.617 | 0.199 | Apoptosis antagonist | 0.199 0.18 CID_154699763 | CID_154699763 | |
| 0.021 | 0.586 | 0.151 | DNA methyltransferase I inhibitor | 0.151 0.103 CID_154699763 | CID_154699763 | |
| 0.043 | 0.62 | 0.238 | Vasodilator, coronary | 0.238 0.147 CID_154699763 | CID_154699763 | |
| 0.004 | 0.587 | 0.015 | Adenosine A2b receptor agonist | 0.015 0.009 CID_154699763 | CID_154699763 | |
| 0.009 | 0.617 | 0.166 | Topoisomerase I inhibitor | 0.166 0.035 CID_154699763 | CID_154699763 | |
| 0.033 | 0.645 | 0.184 | Hepatoprotectant | 0.184 0.076 CID_154699763 | CID_154699763 | |
| 0.019 | 0.64 | 0.158 | Antioxidant | 0.158 0.155 CID_154699763 | CID_154699763 | |
| 0.016 | 0.638 | 0.248 | Angiogenesis stimulant | 0.248 0.071 CID_154699763 | CID_154699763 | |
| 0.018 | 0.655 | 0.15 | DNA methylase inhibitor | 0.15 0.117 CID_154699763 | CID_154699763 | |
| 0.003 | 0.645 | 0.036 | Adenosine A1 receptor agonist | 0.036 0.009 CID_154699763 | CID_154699763 | |
| 0.021 | 0.677 | 0.166 | DNA polymerase I inhibitor | 0.166 0.041 CID_154699763 | CID_154699763 | |
| 0.014 | 0.768 | 0.306 | Antibacterial | 0.306 0.13 CID_154699763 | CID_154699763 | |
| 0.011 | 0.768 | 0.192 | DNA synthesis inhibitor | 0.192 0.135 CID_154699763 | CID_154699763 | |
| 0.023 | 0.784 | 0.328 | Apoptosis agonist | 0.328 0.153 CID_154699763 | CID_154699763 | |
| 0.02 | 0.791 | 0.186 | Hypoglycemic | 0.186 0.127 CID_154699763 | CID_154699763 | |
| 0.003 | 0.793 | 0.016 | S-adenosyl-L-homocysteine hydrolase inhibitor | 0.016 0.009 CID_154699763 | CID_154699763 | |
| 0.053 | 0.883 | 0.3 | Peptidyltransferase inhibitor | 0.3 0.025 CID_154699763 | CID_154699763 | |
| 0.001 | 0.969 | 0.024 | Purinergic P2X agonist | 0.024 0.021 CID_154699763 | CID_154699763 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |